Perioperative Complications of Transurethral Resection of Bladder Tumor in Patients Receiving Antithrombotic Therapy

IR HANDLE Web Site Open Access
  • Wada, Naoki
    The Department of Renal and Urologic Surgery, Asahikawa Medical University
  • Okazaki, Satoshi
    The Department of Renal and Urologic Surgery, Asahikawa Medical University
  • Kobayashi, Shin
    The Department of Renal and Urologic Surgery, Asahikawa Medical University
  • Hashizume, Kazumi
    The Department of Renal and Urologic Surgery, Asahikawa Medical University
  • Hori, Junichi
    The Department of Renal and Urologic Surgery, Asahikawa Medical University
  • Azumi, Makoto
    The Department of Renal and Urologic Surgery, Asahikawa Medical University
  • Kita, Masafumi
    The Department of Renal and Urologic Surgery, Asahikawa Medical University
  • Iwata, Tatsuya
    The Department of Renal and Urologic Surgery, Asahikawa Medical University
  • Matsumoto, Seiji
    The Department of Renal and Urologic Surgery, Asahikawa Medical University
  • Kakizaki, Hidehiro
    The Department of Renal and Urologic Surgery, Asahikawa Medical University

Bibliographic Information

Other Title
  • 抗血栓薬内服患者における経尿道的膀胱腫瘍切除術の周術期合併症
  • コウケッセンヤク ナイフク カンジャ ニ オケル ケイ ニョウドウテキ ボウコウ シュヨウ セツジョジュツ ノ シュウジュツキ ガッペイショウ

Search this article

Abstract

We examined perioperative complications of transurethral resection of bladder tumor (TURBT) in patients receiving antithrombotic therapy. We retrospectively studied 276 patients who underwent TURBT in our institute from January 2007 to March 2013. The study group consisted of 105 patients (38%) who were receiving antithrombotic agents, and the other 171 patients (62%) without antithrombotic agents were assigned to the control group. The period of discontinuation of antithrombotic agents complied with our institutional rule. The most frequently used agent was aspirin (69 patients : 66%), followed by warfarin (25 patients : 24%). Fourteen patients receiving warfarin (56%) needed heparin bridging therapy. There was no significant difference in average operative time (51 minutes versus 54 minutes), or average days to removal of urethral catheter (3.7 days versus 3.3 days) between the study and control groups. Hemorrhagic and ischemic complications were noted in 11 (10.5%) and 2 (1.9%) patients in the study group and 11 (6.4%) and none (0%) of the patients in the control group, respectively, with no significant difference between the 2 groups. However, prevalence of hemorrhagic complications in patients receiving heparin bridging therapy (21.4%) was significantly higher than that in the control group. Ischemic complications in the study group included chest pain suggestive of angina in one patient and acute myocardial infarction leading to death in another patient. We should pay attention to hemorrhagic complications in patients receiving heparin bridging therapy and keep in mind the possibility of lethal ischemic complications after discontinuation of antithrombotic agents.

Journal

  • Hinyokika Kiyo

    Hinyokika Kiyo 60 (11), 531-535, 2014-11

    泌尿器科紀要刊行会

Keywords

Details 詳細情報について

Report a problem

Back to top